NO20045345L - Farmasoytisk doseringsform - Google Patents

Farmasoytisk doseringsform

Info

Publication number
NO20045345L
NO20045345L NO20045345A NO20045345A NO20045345L NO 20045345 L NO20045345 L NO 20045345L NO 20045345 A NO20045345 A NO 20045345A NO 20045345 A NO20045345 A NO 20045345A NO 20045345 L NO20045345 L NO 20045345L
Authority
NO
Norway
Prior art keywords
desmopressin
dosage form
pharmaceutical dosage
formulated
way
Prior art date
Application number
NO20045345A
Other languages
English (en)
Other versions
NO335167B1 (no
Inventor
Anders Nilsen
Hans Lindner
Jorgen Wittendorff
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0210397.6A external-priority patent/GB0210397D0/en
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20045345L publication Critical patent/NO20045345L/no
Publication of NO335167B1 publication Critical patent/NO335167B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

God biotilgjengelighet av desmopressin kan bli oppnådd ved hjelp av en orodispersibel farmasøytisk doseringsform. Foretrukne doseringsformer omfatter desmopressin og et åpent matrisenettverk som er et inert vannoppløselig eller vanndispergerbart bærermateriale. Desmopressin formulert på denne måten er anvendelig for utsettelse av avføring eller .til behandling eller forebygning av inkontinens, primær nattlig enurese (PNE), nokturia eller sentral diabetes insipidus. Peptider andre enn desmopressin kan også bli formulert på denne måten.
NO20045345A 2002-05-07 2004-12-06 Farmasøytisk doseringsform NO335167B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210397.6A GB0210397D0 (en) 2002-05-07 2002-05-07 Pharmaceutical formulations
PCT/IB2002/004036 WO2003094885A1 (en) 2002-05-07 2002-09-20 Sublingual pharmaceutical formulation of desmopressin
PCT/IB2003/002368 WO2003094886A2 (en) 2002-05-07 2003-05-07 Desmopressin in an orodispersible dosage form

Publications (2)

Publication Number Publication Date
NO20045345L true NO20045345L (no) 2005-02-07
NO335167B1 NO335167B1 (no) 2014-10-06

Family

ID=29422105

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045345A NO335167B1 (no) 2002-05-07 2004-12-06 Farmasøytisk doseringsform

Country Status (10)

Country Link
JP (1) JP2006502972A (no)
AU (1) AU2003233118B8 (no)
BR (1) BR0309819A (no)
CA (1) CA2484724C (no)
DE (2) DE60307082D1 (no)
HR (1) HRP20041152B1 (no)
NO (1) NO335167B1 (no)
NZ (1) NZ535861A (no)
PT (1) PT1501534E (no)
WO (1) WO2003094886A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US7022340B2 (en) 2003-07-25 2006-04-04 Ferring B.V. Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP2322195A2 (en) * 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
ES2260563T3 (es) * 2003-11-13 2006-11-01 Ferring B.V. Paquete de blister y forma farmaceutica solida para ello.
CA2490601C (en) * 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
SI1550439T1 (sl) * 2003-12-29 2006-08-31 Ferring Bv Postopek za pripravo trdne dozirne oblike dezmopresina
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
GB0406048D0 (en) * 2004-03-18 2004-04-21 Ardana Bioscience Ltd Drug formulations
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
WO2007098945A2 (en) * 2006-03-02 2007-09-07 Ferring International Center S.A. Stable solid dosage form comprising desmopressin
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
WO2009015037A2 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
RU2472539C2 (ru) * 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
EP2628727A3 (en) 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PT3085381T (pt) * 2008-05-21 2018-05-18 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado pela noctúria
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
TWI468157B (zh) * 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
KR20120104512A (ko) 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절체, 이의 제조 방법, 및 그의 용도
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
AU2011234637B2 (en) * 2010-03-29 2013-08-29 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR083361A1 (es) * 2010-10-08 2013-02-21 Scherer Technologies Inc R P Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
JP2011116764A (ja) * 2011-02-08 2011-06-16 Fine Seymour H 低用量デスモプレシンを含有する医薬組成物
CA2848785A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CN103993061B (zh) * 2014-05-20 2018-03-23 海南美合泰生物科技有限公司 一种鱼胶原蛋白的生产方法
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
JP6341777B2 (ja) * 2014-06-30 2018-06-13 リプリーズ バイオファーマシューティクス，エルエルシー 低用量デスモプレシンを含有する医薬組成物
CA3046725A1 (en) 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
DE102017104472A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
JP3253127B2 (ja) * 1991-06-07 2002-02-04 帝國製薬株式会社 生理活性ポリペプチド含有製剤
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5298256A (en) * 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
EP1146800A1 (en) * 1999-01-27 2001-10-24 Spenco Medical Corporation Therapeutic magnetic insoles
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions

Also Published As

Publication number Publication date
HRP20041152A2 (en) 2005-04-30
JP2006502972A (ja) 2006-01-26
CA2484724C (en) 2007-01-16
PT1501534E (pt) 2006-09-29
DE60307082D1 (de) 2006-09-07
DE60307082T2 (de) 2007-01-18
WO2003094886A3 (en) 2004-07-22
NZ535861A (en) 2006-11-30
BR0309819A (pt) 2005-03-01
CA2484724A1 (en) 2003-11-20
WO2003094886A2 (en) 2003-11-20
AU2003233118B2 (en) 2006-10-26
DE60307082T4 (de) 2015-04-30
AU2003233118B8 (en) 2009-07-30
NO335167B1 (no) 2014-10-06
AU2003233118A1 (en) 2003-11-11
HRP20041152B1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
NO20045345L (no) Farmasoytisk doseringsform
Hernaez et al. Dynamin-and clathrin-dependent endocytosis in African swine fever virus entry
Schultz et al. Variable inhibition of Zika virus replication by different Wolbachia strains in mosquito cell cultures
AR039794A1 (es) Formulaciones farmaceuticas de desmopresina
WO2003061584A3 (en) Novel substituted benzimidazole dosage forms and method of using same
Yi et al. Discovery of novel small-molecule inhibitors of LIM domain kinase for inhibiting HIV-1
YU75903A (sh) Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
AU2003253125A1 (en) Cell penetrating peptides
NO20024891L (no) Farmasöytiske sammensetninger
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
ATE507697T1 (de) Steuerungsverfahren für anrufübergabe, sprachanrufkontinuitätsserver und system zur bereitstellung von sprachanrufkontinuität
BR0215035A (pt) Métodos para operar uma rede de telefonia móvel, e uma pluralidade de redes de telefonia móveis, e, rede de telefonia móvel
Evans et al. BPIFB3 regulates endoplasmic reticulum morphology to facilitate flavivirus replication
Crotty et al. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein
El Kasmi et al. Extended synaptotagmin 1 interacts with herpes simplex virus 1 glycoprotein M and negatively modulates virus-induced membrane fusion
Acchioni et al. Alternate NF-κB-independent signaling reactivation of latent HIV-1 provirus
CA2482503A1 (en) Apparatus and method for handling cell update during reconfiguration in universal mobile telecommunications system user equipment
Ducasa et al. Autophagy in human T-cell leukemia virus type 1 (HTLV-1) induced leukemia
Tham et al. Protein-protein interactions between A. aegypti midgut and dengue virus 2: two-hybrid screens using the midgut cDNA library
Limonta et al. Nodosome inhibition as a novel broad-spectrum antiviral strategy against arboviruses, enteroviruses, and SARS-CoV-2
Milush et al. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques
Kakumani et al. Role of human GRP75 in miRNA mediated regulation of dengue virus replication
Jimenez et al. β-catenin restricts Zika virus Internalization by downregulating Axl
Mielke et al. Selection of HIV envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity-mediating antibodies
AU1599601A (en) Human igm antibodies to chemokine receptors

Legal Events

Date Code Title Description
MK1K Patent expired